Cargando…
Identification of international metastatic renal cell carcinoma database consortium (IMDC) intermediate-risk subgroups in patients with metastatic clear-cell renal cell carcinoma
Majority of patients with clear-cell renal cell carcinoma (ccRCC) at first line (1L) treatment are classified in the intermediate-risk (IR) subgroup according to International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) score. As these patients have different prognosis, the aim of thi...
Autores principales: | Guida, Annalisa, Le Teuff, Gwénaël, Alves, Carolina, Colomba, Emeline, Di Nunno, Vincenzo, Derosa, Lisa, Flippot, Ronan, Escudier, Bernard, Albiges, Laurence |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7733622/ https://www.ncbi.nlm.nih.gov/pubmed/33346231 http://dx.doi.org/10.18632/oncotarget.27762 |
Ejemplares similares
-
Weight and skeletal muscle loss with cabozantinib in metastatic renal cell carcinoma
por: Colomba, Emeline, et al.
Publicado: (2022) -
Hypertension and Angiotensin System Inhibitors in Patients with Metastatic Renal Cell Carcinoma
por: Derosa, Lisa, et al.
Publicado: (2016) -
Outcomes of Metastatic Chromophobe Renal Cell Carcinoma (chrRCC) in the Targeted Therapy Era: Results from the International Metastatic Renal Cell Cancer Database Consortium (IMDC)
por: Yip, Steven M., et al.
Publicado: (2017) -
Association of cabozantinib pharmacokinetics, progression and toxicity in metastatic renal cell carcinoma patients: results from a pharmacokinetics/pharmacodynamics study
por: Cerbone, L., et al.
Publicado: (2021) -
Tyrosine kinase inhibitors and immunotherapy combinations in renal cell carcinoma
por: Rassy, Elie, et al.
Publicado: (2020)